Small ubiquitin-related modifier pathway is a major determinant of doxorubicin cytotoxicity in Saccharomyces cerevisiae

Cancer Research

Volumn 67, Issue 2, 2007, Pages 765-772

  Huang, Ruea Yea ^a   Kowalski, David ^a   Minderman, Hans ^a   Gandhi, Nishant ^b   Johnson, Erica S ^b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; CELL NUCLEUS ANTIGEN; CISPLATIN; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IRINOTECAN; LIGASE; MLP1 ENZYME; MMS21 ENZYME; NUP60 ENZYME; SEPTIN; SIZ1 ENZYME; SIZ2 ENZYME; SUMO PROTEIN; UBA2 ENZYME; UBC9 ENZYME; UBIQUITIN CONJUGATING ENZYME; UBIQUITIN PROTEIN LIGASE; UIP3 ENZYME; ULP1 ENZYME; ULP2 ENZYME; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE ARREST; CELL LEVEL; CONTROLLED STUDY; CYTOTOXICITY; DESUMOYLATION; DNA REPAIR; DRUG ACCUMULATION; DRUG RETENTION; DRUG SENSITIVITY; FUNGUS MUTANT; GENE DELETION; GENE MUTATION; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; SACCHAROMYCES CEREVISIAE; SUMOYLATION;

ANTIBIOTICS, ANTINEOPLASTIC; CELL CYCLE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE DELETION; PROLIFERATING CELL NUCLEAR ANTIGEN; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 33846676764     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2839     Document Type: Article

References (53)

1. Wang JC. DNA topoisomerases. Annu Rev Biochem 1996;65:635-92.
2. Crooke ST, Duvernay VH, Galvan L, Prestayko AW. Structure-activity relationships of anthracyclines relative to effects on macromolecular syntheses. Mol Pharmacol 1978;14:290-8.
3. Meriwether WD, Bachur NR. Inhibition of DNA and RNA metabolism by daunorubicin and adriamycin in L1210 mouse leukemia. Cancer Res 1972;32:1137-42.
4. Ross WE, Glaubiger DL, Kohn KW. Protein-associated DNA breaks in cells treated with adriamycin or ellipticine. Biochim Biophys Acta 1978;519:23-30.
5. Lown JW, Sim SK, Majumdar KC, Chang RY. Strand scission of DNA by bound adriamycin and daunorubicin in the presence of reducing agents. Biochem Biophys Res Commun 1977;76:705-10.
6. Tritton TR, Hickman JA. How to kill cancer cells: membranes and cell signaling as targets in cancer chemotherapy. Cancer Cells 1990;2:95-105.
7. Binaschi M, Giaccone G, Gazdar AF, et al. Characterization of a topoisomerase II gene rearrangement in a human small-cell lung cancer cell line. J Natl Cancer Inst 1992;84:1710-6.
8. Haimeur A, Conseil G, Deeley RG, Cole SP. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity, and regulation. Curr Drug Metab 2004;5:21-53.
9. Bellamy WT, Dalton WS, Meltzer P, Dorr RT. Role of glutathione and its associated enzymes in multidrug-resistant human myeloma cells. Biochem Pharmacol 1989;38:787-93.
10. Lau DH, Lewis AD, Ehsan MN, Sikic BI. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. Cancer Res 1991;51:5181-7.
11. Conklin KA. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity. Integr Cancer Ther 2005;4:110-30.
12. Huang RY, Eddy M, Vujcic M, Kowalski D. Genome-wide screen identifies genes whose inactivation confer resistance to cisplatin in Saccharomyces cerevisiae. Cancer Res 2005;65:5890-7.
13. Johnson ES. Protein modification by SUMO. Annu Rev Biochem 2004;73:355-82.
14. Zhao X, Blobel G. A SUMO ligase is part of a nuclear multiprotein complex that affects DNA repair and chromosomal organization. Proc Natl Acad Sci U S A 2005;102:4777-82.
15. Cheng CH, Lo YH, Liang SS, et al. SUMO modifications control assembly of synaptonemal complex and polycomplex in meiosis of Saccharomyces cerevisiae. Genes Dev 2006;20:2067-81.
16. Potts PR, Yu H. Human MMS21/NSE2 is a SUMO ligase required for DNA repair. Mol Cell Biol 2005;25:7021-32.
17. Nacerddine K, Lehembre F, Bhaumik M, et al. The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice. Dev Cell 2005;9:769-79.
18. Winzeler EA, Shoemaker DD, Astromoff A, et al. Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science 1999;285:901-6.
19. Sherman F. Getting started with yeast. Methods Enzymol 1991;194:3-21.
20. Johnson ES, Schwienhorst I, Dohmen RJ, Blobel G. The ubiquitin-like protein Smt3p is activated for conjugation to other proteins by an Aos1p/Uba2p heterodimer. EMBO J 1997;16:5509-19.
21. Bachant J, Alcasabas A, Blat Y, Kleckner N, Elledge SJ. The SUMO-1 isopeptidase Smt4 is linked to centromeric cohesion through SUMO-1 modification of DNA topoisomerase II. Mol Cell 2002;9:1169-82.
22. Young IT. Proof without prejudice: use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources. J Histochem Cytochem 1977;25:935-41.
23. Minderman H, Suvannasankha A, O'Loughlin KL, et al. Flow cytometric analysis of breast cancer resistance protein expression and function. Cytometry 2002;48:59-65.
24. Takahashi Y, Mizoi J, Toh EA, Kikuchi Y. Yeast Ulp1, an Smt3-specific protease, associates with nucleoporins. J Biochem (Tokyo) 2000;128:723-5.
25. Zhao X, Wu CY, Blobel G. Mlp-dependent anchorage and stabilization of a desumoylating enzyme is required to prevent clonal lethality. J Cell Biol 2004;167:605-11.
26. Bylebyl GR, Belichenko I, Johnson ES. The SUMO isopeptidase Ulp2 prevents accumulation of SUMO chains in yeast. J Biol Chem 2003;278:44113-20.
27. Johnson ES, Blobel G. Ubc9p is the conjugating enzyme for the ubiquitin-like protein Smt3p. J Biol Chem 1997;272:26799-802.
28. Johnson ES, Gupta AA. An E3-like factor that promotes SUMO conjugation to the yeast septins. Cell 2001;106:735-44.
29. Zhou W, Ryan JJ, Zhou H. Global analyses of sumoylated proteins in Saccharomyces cerevisiae: induction of protein sumoylation by cellular stresses. J Biol Chem 2004;279:32262-8.
30. Hoege C, Pfander B, Moldovan GL, Pyrowolakis G, Jentsch S. RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. Nature 2002;419:135-41.
31. Johnson ES, Blobel G. Cell cycle-regulated attachment of the ubiquitin-related protein SUMO to the yeast septins. J. Cell Biol 1999;147:981-94.
32. Panse VG, Hardeland U, Werner T, Kuster B, Hurt E. A proteome-wide approach identifies sumoylated substrate proteins in yeast. J Biol Chem 2004;279:41346-51.
33. Vertegaal ACO, Ogg SC, Jaffray E, et al. A proteomic study of SUMO-2 target proteins. J Biol Chem 2004;279:33791-8.
34. Wohlschlegel JA, Johnson ES, Reed SI, Yates JR III. Global analysis of protein sumoylation in Saccharomyces cerevisiae. J Biol Chem 2004;279:45662-8.
35. Takahashi Y, Yong-Gonzalez V, Kikuchi Y, Strunnikov A. SIZ1/SIZ2 control of chromosome transmission fidelity is mediated by the sumoylation of topoisomerase II. Genetics 2006;172:783-94.
36. Rose D, Thomas W, Holm C. Segregation of recombined chromosomes in meiosis I requires DNA topoisomerase II. Cell 1990;60:1009-17.
37. Meczes EL, Marsh KL, Fisher LM, Rogers MP, Austin CA. Complementation of temperature-sensitive topoisomerase II mutations in Saccharomyces cerevisiae by a human TOP2β construct allows the study of topoisomerase IIβ inhibitors in yeast. Cancer Chemother Pharmacol 1997;39:367-75.
38. Papouli E, Chen S, Davies AA, et al. Crosstalk between SUMO and ubiquitin on PCNA is mediated by recruitment of the helicase Srs2p. Mol Cell 2005;19:123-33.
39. Pfander B, Moldovan GL, Sacher M, Hoege C, Jentsch S. SUMO-modified PCNA recruits Srs2 to prevent recombination during S phase. Nature 2005;436:428-33.
40. 2 arrests in HL-60 cells. Br J Haematol 1999;105:720-9.
41. Kolaczkowski M, van der Rest M, Cybularz-Kolaczkowska A, Soumillion JP, Konings WN, Goffeau A. Anticancer drugs, ionophoric peptides, and steroids as substrates of the yeast multidrug transporter Pdr5p. J Biol Chem 1996;271:31543-8.
42. Katzmann DJ, Burnett PE, Golin J, Mahe Y, Moye-Rowley WS. Transcriptional control of the yeast PDR5 gene by the PDR3 gene product. Mol Cell Biol 1994;14:4653-61.
43. Nitiss J, Wang JC. DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc Natl Acad Sci U S A 1988;85:7501-5.
44. Jacquiau HR, van Waardenburg RC, Reid RJ, et al. Defects in SUMO (small ubiquitin-related modifier) conjugation and deconjugation alter cell sensitivity to DNA topoisomerase I-induced DNA damage. J Biol Chem 2005;280:23566-75.
45. Mo YY, Yu Y, Ee PL, Beck WT. Overexpression of a dominant-negative mutant Ubc9 is associated with increased sensitivity to anticancer drugs. Cancer Res 2004;64:2793-8.
46. Li SJ, Hochstrasser M. The yeast ULP2 (SMT4) gene encodes a novel protease specific for the ubiquitin-like Smt3 protein. Mol Cell Biol 2000;20:2367-77.
47. Meluh PB, Koshland D. Evidence that the MIF2 gene of Saccharomyces cerevisiae encodes a centromere protein with homology to the mammalian centromere protein CENP-C. Mol Biol Cell 1995;6:793-807.
48. Li SJ, Hochstrasser M. The Ulp1 SUMO isopeptidase: distinct domains required for viability, nuclear envelope localization, and substrate specificity. J Cell Biol 2003;160:1069-81.
49. Hay RT. SUMO: a history of modification. Mol Cell 2005;18:1-12.
50. Spiliotis ET, Nelson WJ. Here come the septins: novel polymers that coordinate intracellular functions and organization. J Cell Sci 2006;119:4-10.
51. Kartmann B, Roth D. Novel roles for mammalian septins: from vesicle trafficking to oncogenesis. J Cell Sci 2001;114:839-44.
52. Mao Y, Desai SD, Liu LF. SUMO-1 conjugation to human DNA topoisomerase II isozymes. J Biol Chem 2000;275:26066-73.
53. Wolfger H, Mahe Y, Parle-McDermott A, Delahodde A, Kuchler K. The yeast ATP binding cassette (ABC) protein genes PDR10 and PDR15 are novel targets for the Pdr1 and Pdr3 transcriptional regulators. FEBS Lett 1997;418:269-74.